Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study

被引：0

作者：

Coleman, Robert ^{[1
]}

Oaknin, Ana ^{[2
]}

Pignata, Sandro ^{[3
]}

Denys, Hannelore ^{[4
]}

Colombo, Nicoletta ^{[5
]}

Van Gorp, Toon ^{[6
]}

Konner, Jason ^{[7
]}

Marin, Margarita Romeo ^{[8
]}

Harter, Philipp ^{[9
]}

Murphy, Conleth ^{[10
]}

Esteves, Brooke ^{[11
]}

Method, Michael ^{[11
]}

Lorusso, Domenica ^{[12
]}

Matulonis, Ursula ^{[13
]}

机构：

[1] US Oncol Res, The Woodlands, TX USA

[2] Vall Hebron Inst Oncol, Barcelona, Spain

[3] Ist Nazl Tumori Napoli Fdn G Pascale, Naples, Italy

[4] Ghent Univ Hosp, Ghent, Belgium

[5] European Inst Oncol IRCCS, Milan, Italy

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[9] Kliniken Essen Mitte, Essen, Germany

[10] Bon Secours Hosp Cork & Canc Trials, Cork, Ireland

[11] ImmunoGen Inc, Waltham, MA USA

[12] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[13] Dana Farber Canc Inst, Boston, MA USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 176卷

关键词：

D O I：

10.1016/j.ygyno.2023.06.468

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

002

引用

页码：S3 / S3

页数：1

共 50 条

[31] A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Trillsch, Fabian
Schochter, Fabienne
Park-Simon, Tjoung-Won
Reuss, Alexander
Fehm, Tanja N.
Wimberger, Pauline
Bronger, Holger
Schmalfeldt, Barbara
Sehouli, Jalid
Marme, Frederik
Heitz, Florian
Mahner, Sven
Fredrich, Michaela
Barth, Stefanie
Stec, James Joseph
Method, Michael W.
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Richardson, Debra L.
Moore, Kathleen N.
Vergote, Ignace
Gilbert, Lucy
Martin, Lainie P.
Mantia-Smaldone, Gina M.
Castro, Cesar M.
Provencher, Diane
Matulonis, Ursula A.
Stec, James
Wang, Yuemei
Method, Michael
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2024, 185 : 186 - 193
[33] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
O'Malley, David M.
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Zweidler-McKay, Patrick A.
Wang, Jiuzhou
Esteves, Brooke
Moore, Kathleen N.
Gilbert, Lucy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Clinical Response to Antiestrogen Therapy in Platinum-Resistant Ovarian Cancer Patients and the Role of Tumor Estrogen Receptor Expression Status
Stasenko, Marina
Plegue, Melissa
Sciallis, Andrew P.
McLean, Karen
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (02) : 222 - 228
[35] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, Kathleen N.
O'Malley, David M.
Vergote, Ignace
Martin, Lainie P.
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 46 - 52
[36] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana N.
Oza, Amit M.
Pautier, Patricia
Kelly, Catherine Margaret
Malek, Karim S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37] FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
Moore, K. N.
Vergote, I.
Oaknin, A.
Colombo, N.
Banerjee, S.
Oza, A. M.
Pautier, P.
Kelly, C. M.
Malek, K.
Birrer, M. J.
ANNALS OF ONCOLOGY, 2017, 28
[38] Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator's choice chemotherapy: analysis from the phase 3 MIRASOL trial
Garcia, Yolanda Garcia
Gorp, Toon Van
Konecny, Gottfried E.
Leary, Alexandra
Santin, Alessandro D.
Crusz, Shanthini Mary
Mantia-Smaldone, Gina
Lorusso, Domenica
Colombo, Nicoletta
Thomes-Pepin, Jessica
Roszak, Andrzej
Ottevanger, Petronella B.
Beiner, Mario
Cibula, David
Leath, Charles
Li, Lingling
Method, Michael
Moore, Kathleen N.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A34 - A35
[39] PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI-FOLATE RECEPTOR ALPHA (FRα) ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED PLATINUM-RESISTANT/REFRACTORY EPITHELIAL OVARIAN CANCER (OC)
Naumann, R.
Braiteh, F.
Diaz, J.
Hamilton, E.
Diab, S.
Schilder, R.
Moroney, J.
Martin, L.
Uyar, D.
O'Malley, D.
Penson, R.
DiLea, C.
Palumbo, M.
DeAlmeida, V.
Berman, C.
Matheny, S.
Molina, A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A61 - A61
[40] PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression
Secord, Angeles Alvarez
Lewin, Sharyn
Murphy, Conleth
Method, Michael
GYNECOLOGIC ONCOLOGY, 2022, 166 : S157 - S158

← 1 2 3 4 5 →